Immunome’s Promising Pipeline and Strategic Advancements Support Buy Rating

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Immunome (IMNM – Research Report) yesterday and set a price target of $20.00.

Charles Zhu has given his Buy rating due to a combination of factors that highlight Immunome’s promising prospects. The company has reiterated its progress on key pipeline achievements, including the anticipated Phase 3 clinical trial results for varegacestat, an oral gamma secretase inhibitor for desmoid tumors, expected in the second half of 2025. This potential registration milestone could significantly impact the company’s valuation, especially considering the recent acquisition of SpringWorks and the valuation disparity between the two companies.
Additionally, Immunome’s management expresses confidence in the drug’s efficacy and convenience, particularly its once-daily dosing advantage over competitors. The company also announced the IND clearance for its FAP-targeted RLT, IM-3050, with plans to initiate a Phase 1 trial soon. With a strong cash position and an operating runway into 2027, Immunome is well-positioned to advance its pipeline and capitalize on upcoming milestones, supporting the Buy rating.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMNM in relation to earlier this year.